These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 17553812)

  • 1. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
    J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
    Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
    Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
    Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
    Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
    Schaper NC; Dryden M; Kujath P; Nathwani D; Arvis P; Reimnitz P; Alder J; Gyssens IC
    Infection; 2013 Feb; 41(1):175-86. PubMed ID: 23180507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
    Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A;
    Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
    Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
    J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
    Graham DR; Lucasti C; Malafaia O; Nichols RL; Holtom P; Perez NQ; McAdams A; Woods GL; Ceesay TP; Gesser R
    Clin Infect Dis; 2002 Jun; 34(11):1460-8. PubMed ID: 12015692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
    Lipsky BA; Armstrong DG; Citron DM; Tice AD; Morgenstern DE; Abramson MA
    Lancet; 2005 Nov; 366(9498):1695-703. PubMed ID: 16291062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
    File TM; Tan JS
    Eur J Surg Suppl; 1994; (573):51-5. PubMed ID: 7524796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S; Higareda I; Angel-Muller E; Ismail M; Hague C; Adeyi B; Woods GL; Teppler H;
    Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
    Philpott-Howard J; Burroughs A; Fisher N; Hastings M; Kibbler C; Mutimer D; Patch D; Rolando N; Wade J; Wendon J; O'Grady J
    J Antimicrob Chemother; 2003 Dec; 52(6):993-1000. PubMed ID: 14585863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
    Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
    Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.